Ohio State standout wide receiver Carnell Tate announced on Tuesday he is leaving school early to declare for the NFL draft.
Tate announced his decision on social media. The junior had 51 receptions for 875 yards and nine touchdowns this season as he became a deep threat in the Buckeyes' passing attack.
Tate — an AP second-team All-American — had nine receptions of at least 40 yards, tied for third in the Football Bowl Subdivision, including five touchdowns. After missing three games in November because of lower leg tightness, Tate returned against Michigan and put the game out of reach with a 50-yard TD that made it 24-9 midway through the third quarter.
“I'm proud of everything I've accomplished at Ohio State and will carry the lessons, relationships, and memories from this program with me forever,” Tate wrote.
Tate is expected to become the sixth OSU receiver selected in the first round since 2022, joining Garrett Wilson and Chris Olave (2022), Jaxon Smith-Njigba (2023), Marvin Harrison Jr. (2024) and Emeka Egbuka (2025).
Ohio State's offense will have some changes after finishing 12-2 and losing to Miami in the College Football Playoff quarterfinal at the Cotton Bowl. Besides Tate's departure, offensive coordinator and receivers coach Brian Hartline has become the head coach at South Florida.
Coach Ryan Day announced last week he hired Cortez Hankton as receivers coach. Hankton had spent four seasons at LSU, including the past two as receivers coach and co-offensive coordinator.
Day though remains in the market for an offensive coordinator.
Even with Tate's departure, the Buckeyes will have plenty of talent in the passing game. First-team All-American Jeremiah Smith will be back for one more season along with quarterback Julian Sayin. Five-star prospect Chris Henry Jr. committed to the Buckeyes during the early signing period.
Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here and here (AP News mobile app). AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
Ohio State wide receiver Carnell Tate runs the ball against Miami during the second half of the Cotton Bowl College Football Playoff quarterfinal game Wednesday, Dec. 31, 2025, in Arlington, Texas. (AP Photo/Gareth Patterson)
Ohio State wide receiver Carnell Tate runs after making a catch against Miami during the first half of the Cotton Bowl College Football Playoff quarterfinal game Wednesday, Dec. 31, 2025, in Arlington, Texas. (AP Photo/Gareth Patterson)
LILLE, France & PARIS--(BUSINESS WIRE)--Jan 8, 2026--
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/
The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across Europe, Canada, and now the U.S., reinforcing the company’s role as a front-runner in the race to deliver the first disease-modifying osteoarthritis drug (DMOAD) to patients worldwide. Preclinical studies have shown that 4P004 can modulate multiple biological markers across the whole joint, supporting its potential as a first-in-class DMOAD capable of slowing structural impairment and improving joint function.
“FDA’s clearance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe, Canada, and the United States,” said Luc Boblet, Chief Executive Officer of 4Moving Biotech. “This milestone strengthens our position as one of the most advanced DMOAD developers globally and brings us closer to demonstrating the transformative potential of 4P004 for the millions of patients worldwide who currently have no disease-modifying options.”
The INFLAM MOTION trial is a 3-month, multicenter, randomized, double-blind, placebo-controlled Phase 2a study designed to enroll 129 patients suffering from knee osteoarthritis with synovitis. The trial includes:
This unique combination of clinical, imaging, and biomarker elements forms the foundation for future interactions with regulatory agencies on accelerated or conditional approval pathways, thereby strategically positioning 4P004 within the highest-priority segment of OA drug development.
“4P004, a GLP-1 receptor agonist administered intra-articularly, allows specific targeting of the diseased joint and joint tissues, aiming to relieve pain while also addressing the underlying disease process, thus offering an exciting novel approach for patients living with painful knee osteoarthritis. As the U.S. Coordinating Investigator, I am pleased to support the INFLAM MOTION study and look forward to evaluating this promising therapeutic approach for patients with knee osteoarthritis.”Thomas J. Schnitzer, MD, PhD,Professor of Medicine,Northwestern University
Professor Francis Berenbaum, MD, PhD, Chief Medical Officer of 4MovingBiotech, concluded: “The regulatory progress across three major regions underscores the scientific robustness of 4P004. INFLAM MOTION is designed to deliver clinically meaningful pain improvement while generating high-resolution structural and biological data to guide the next stage of development. We believe 4P004 has the potential to redefine how osteoarthritis is treated.”
4Moving Biotech will initiate patient enrollment in the United States in Q1 2026, following site activation and investigator onboarding.
About 4Moving Biotech
Founded in 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical-stage biotechnology company developing disease-modifying drugs for osteoarthritis, one of the world’s most burdensome chronic diseases, affecting more than 600 million people and lacking approved therapies that alter disease course. Headquartered on the Pasteur Institute campus in Lille, 4MB aims to deliver safe, sustainable therapeutic solutions for patients with high unmet medical needs.
Website: www.4movingbiotech.com
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X : https://x.com/4Moving_Biotech
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).
